Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | RARG | P13631 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 2/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238620 | 0.88 | RARA (0.54) | SMN1; SMN2RARARARBRARGMAPT | |
| SCHEMBL16180612 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPK1RARARARBRARG | |
| SCHEMBL9975608 | 0.79 | TRPM8 (0.46) | SMN1; SMN2MAPK1RARARARBRARG | |
| SCHEMBL8239693 | 0.78 | RARA (0.53) | SMN1; SMN2RARARARBRARGMAPT | |
| SCHEMBL8239864 | 0.77 | RARA (0.52) | SMN1; SMN2RARARARBRARGMAPT | |
| SCHEMBL9975605 | 0.77 | MAPT (0.48) | SMN1; SMN2RARARARBRARGMAPT | |
| SCHEMBL9975604 | 0.77 | RARA (0.51) | SMN1; SMN2RARARARBRARGMAPT | |
| SCHEMBL9975611 | 0.76 | SREBF2 (0.46) | SMN1; SMN2MAPK1MAPTRAB9ANPC1 | |
| SCHEMBL8242411 | 0.75 | MAPT (0.51) | RARARARBRARGMAPTRAB9A | |
| SCHEMBL4926537 | 0.73 | CYP4F2 (0.52) | SMN1; SMN2MAPK1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394798-B2 | Compositions and methods for inducing neuronal differentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120157457-A1 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157457-A1 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-06-21 | — | — | US | disclosed |
| US-8105581-B2 | Compositions and methods for inducing neuronal differentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100166710-A1 | Compositions and Methods for Inducing Neuronal Differentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166710-A1 | Compositions and Methods for Inducing Neuronal Differentiation | CHAT, DCX, GAP43 | SMN1; SMN2 115/4885MAPK1 2190/4885RARA 163/4885 |
| US-20120157457-A1 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION | CHAT, DCX, GAP43 | SMN1; SMN2 115/4885MAPK1 2190/4885RARA 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.